MARKET

CARA

CARA

Cara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.77
-0.18
-1.51%
After Hours: 11.77 0 0.00% 16:47 01/24 EST
OPEN
11.60
PREV CLOSE
11.95
HIGH
11.85
LOW
10.83
VOLUME
698.93K
TURNOVER
--
52 WEEK HIGH
29.65
52 WEEK LOW
10.83
MARKET CAP
629.21M
P/E (TTM)
26.84
1D
5D
1M
3M
1Y
5Y
Cannabis Stock Gainers And Losers From January 18, 2022
GAINERS: Item 9 Labs (OTC:INLB) shares closed up 11.46% at $1.07
Benzinga · 5d ago
Cara Therapeutics Announces Difelikefalin Injection Topline Results In Phase 3 Clinical Study In Japan
Cara Therapeutics, Inc. (NASDAQ:CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its
Benzinga · 01/10 13:33
BRIEF-Cara Therapeutics Inc - Cash Position As Of Dec 31, 2021 Was $237 Million, With 53 Million Shares Of Common Stock Outstanding, And No Debt
reuters.com · 01/10 12:47
Cara Therapeutics wins CMS grants for newly approved pruritus therapy
Cara Therapeutics (NASDAQ:CARA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) greenlighted a form of reimbursement for KORSUVA (difelikefalin) injection in the anti-pruritic functional category. The Transitional
Seekingalpha · 12/20/2021 14:30
BRIEF-Cara Therapeutics Announces CMS Grants Tdapa To Korsuva (Difelikefalin) Injection
reuters.com · 12/20/2021 12:23
Cara Therapeutics Announces The CMS Has Granted Transitional Drug Add-On Payment Adjustment To KORSUVA Injection
Cara Therapeutics, Inc. (NASDAQ:CARA) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted Transitional Drug Add-On Payment Adjustment (TDAPA) to KORSUVA™
Benzinga · 12/20/2021 12:08
Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection
KORSUVA receives TDAPA reimbursement beginning April 2022 U.S. commercial launch on track for early second quarter 2022 STAMFORD, Conn., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Centers for Medi...
GlobeNewswire · 12/20/2021 12:00
Do Institutions Own Cara Therapeutics, Inc. (NASDAQ:CARA) Shares?
If you want to know who really controls Cara Therapeutics, Inc. ( NASDAQ:CARA ), then you'll have to look at the makeup...
Simply Wall St. · 12/14/2021 10:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CARA. Analyze the recent business situations of Cara through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
37.50%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CARA stock price target is 26.25 with a high estimate of 35.00 and a low estimate of 17.00.
High35.00
Average26.25
Low17.00
Current 11.77
EPS
Actual
Estimate
-0.090.430.951.47
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 235
Institutional Holdings: 30.74M
% Owned: 57.50%
Shares Outstanding: 53.46M
TypeInstitutionsShares
Increased
50
3.13M
New
27
722.54K
Decreased
53
1.67M
Sold Out
29
3.69M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
President/Chief Executive Officer/Director
Christopher Posner
Chief Financial Officer
Thomas Reilly
Senior Vice President/Chief Scientific Officer
Frederique Menzaghi
Chief Compliance Officer/General Counsel/Secretary
Scott Terrillion
Other
Joana Goncalves
Lead Director/Independent Director
Martin Vogelbaum
Independent Director
Harrison Bains
Independent Director
Jeffrey Ives
Independent Director
Susan Shiff
No Data
About CARA
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.

Webull offers kinds of Cara Therapeutics Inc stock information, including NASDAQ:CARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CARA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CARA stock methods without spending real money on the virtual paper trading platform.